α9α10 nicotinic acetylcholine receptors (nAChRs) putatively exist at different stoichiometries. We systematically investigated the molecular determinants of α-conotoxins Vc1.1, RgIA#, and PeIA inhibition at hypothetical stoichiometries of the human α9α10 nAChR. Our results suggest that only Vc1.1 exhibits stoichiometric-dependent inhibition at the α9α10 nAChR. The hydrogen bond between N154 of α9 and D11 of Vc1.1 at the α9(+)-α9(−) interface is responsible for the stoichiometric dependent potency of Vc1.1.
Introduction
Nicotinic acetylcholine receptors (nAChRs) are cation-selective pentameric ligand-gated ion channels belonging to the family of Cys-loop receptors, which also includes γ-aminobutyric acid type A (GABA A ), glycine, and serotonin (5-HT 3 ) receptors. 1 The vertebrate nAChRs are homo/heteromeric assembles of α1-α10, β1-β4, γ, δ or ε subunits. Although the nAChRs are generally featured in the nervous system, they are also expressed in non-neuronal cells participating in various physiological events and they are important targets for drug design. 2 The first crystal structure of any heteromeric nAChRs, the human(h) α4β2 nAChR subtype, reveals the overall architecture consisting of a large extracellular domain (ECD), a transmembrane domain (TMD) and an intracellular domain (ICD) ( Figure 1A ). 3 The ligand binding site is located at the ECD interface of two adjacent subunits, comprising of (+) (principal) and (─) (complementary) components. For hα4β2 nAChR, the α4 subunit loops A, B and C form the (+) site, and the β2 subunit β-sheet contributes to the (─) site ( Figure 1B ). Five subunits of the nAChR circle a conducting pore ( Figure 1C ) where a gate consisting of hydrophobic residues, such as Leu and Ile, is located in the middle of the TMD.
Heteromeric α9α10 nAChRs play an important physiological role in mediating olivocochlear and vestibular neurotransmission. 4, 5 Transcripts/protein expression of α9 and/or α10 subunits have been reported in dorsal root ganglion neurons, 6, 7 adrenal medulla, 8 and in other non-neuronal cells, such as skin keratinocytes, pituitary pars tuberalis, lymphocytes, macrophages and bladder urothelium. [9] [10] [11] [12] [13] [14] [15] α9-Containing nAChRs are potential targets for the therapy of several disorders or diseases such as ear disorders, chronic pain and pemphigus vulgaris. 7, 9, 11, 16, 17 In addition, α9-containing nAChRs are responsible for nicotine-induced transformation of normal human breast epithelial cells, and inducible overexpression of α9-nAChR substantially increased tumor growth. 18 Conotoxins derived from the venom of Conus sea snails are pharmacologically valuable peptides with selective potency at nAChR subtypes. α-Conotoxin antagonists of α9α10 nAChR such as C. victoriae Vc1.1, C. regius RgIA (Figure 2 ), and C. generalis GeXIVA are short and well-folded peptides with analgesic effect in rat models of neuropathic pain. 19, 20 In addition, PeIA from C. pergrandis, displays high selectivity for the α9α10 nAChR subtype. 21 Similar to Vc1.1 and RgIA, PeIA is also a potent inhibitor of N-type calcium channels via GABA B receptor activation. 22 Despite their specificity at inhibiting α9α10 nAChRs, the binding site and the stoichiometry-dependent sensitivity of each α-conotoxin are varied. The stoichiometry of rat(r) α9α10 nAChR heterologously expressed in Xenopus laevis oocytes was initially suggested to consist of two α9 and three α10 subunits ((α9) 2 (α10) 3 ). 23 Based on this stoichiometry, Vc1.1 was postulated to bind preferentially at the α10(+)-α9(─) interface. 24 However, Indurthi et al. proposed at least two stoichiometries (see Figure 1D ,E), possibly (α9) 2 (α10) 3 and (α9) 3 (α10) 2 , with a high Vc1.1-sensitive α9(+)-α9(─) binding site present in the (α9) 3 (α10) 2 composition, and two low Vc1.1-sensitive binding sites contributed by the α10(+)-α9(─) and/or α9(+)-α10(─) interfaces that are common in both subunit arrangements. 25 In contrast, RgIA exhibited no preference for the Vc1.1-high sensitivity binding site of the α9α10 nAChR, and it was reported that RgIA has a high affinity for the α10(+)-α9(─) interface. 26 The molecular determinants that govern the binding site selectivity and stoichiometry-dependent sensitivity of Vc1.1, RgIA, and PeIA at α9α10 nAChR, however, remain elusive and the activity of PeIA at different α9α10 nAChR stoichiometries is yet to be reported. In this study, we performed comprehensive computational modeling based on the proposed high and low Vc1.1 sensitivity binding sites in (α9) 2 (α10) 3 and (α9) 3 (α10) 2 stoichiometries, in combination with mutagenesis study on hα9α10 nAChRs expressed in oocytes injected with varied α9:α10 mRNA ratios. The sequences of Vc1.1, RgIA, and PeIA are remarkably different from each other despite their relatively potent antagonism of the α9α10 nAChR. We aim to identify residues of the receptor and/or peptides responsible for the α9α10 nAChR binding site selectivity and sensitivity of these peptides. This information is essential for the design of α-conotoxin analogues with improved selectivity for a specific α9α10 nAChR stoichiometry.
Results and discussion

Molecular dynamics simulations
Vc1.1 was postulated to inhibit α9α10 nAChR by binding at a high affinity α9(+)-α9(─) interface and/or a low affinity α10(+)-α9(─) interface. 24, 25 Both Vc1.1 binding sites share a common α9 subunit (─) component, therefore, the determinants of Vc1.1 binding should be contributed by non-conserved residues of the α9 and α10 subunit (+) components. Overall, our molecular dynamics (MD) simulation model suggests, the binding modes of Vc1.1 at both α9(+)-α9(─) and α10(+)-α9(─)
interfaces are similar with four salt-bridges formed involving charged residues of Vc1.1 (R7, D11, H12 and E14) and conserved residues of the hα9 and hα10 subunits (R81, R113, E197 and D201).
The R7-D201, H12-E197, D11-R81 and E14-R113 hydrogen bonds ( Figure 3A ,B) are consistent with the previously proposed interaction of Vc1.1 with the α10 subunit (+) site residues. 24 In addition to the interaction with R81 of the α9 subunit (─) component, D11 of Vc1.1 forms additional hydrogen bond with a non-conserved N154 at the α9(+)-α9(─) interface ( Figure 3B ). In comparison, the corresponding α10 subunit residue G154 ( Figure 3A ) is incapable of direct interaction with Vc1.1. Other non-conserved α9 and α10 subunit (+) site residues at position 188 and 190 are postulated to have no contribution to the binding affinity of Vc1.1. Our model postulates residues α9 N188 and α10 R188 are not feasibly located to interact with Vc1.1, whereas residues α9 I190 and α10 L190 have similar side chains.
In this study, we used the R13-deleted analogue of RgIA (RgIA#) to probe its sensitivity to different stoichiometries of α9α10 nAChRs. RgIA# has been reported to have comparable activity to the wild-type RgIA. 27, 28 RgIA# has an internal salt-bridge formed between residues D5 and R7, involved in binding at both α10(+)-α9() and to α9(+)-α9() interfaces. At both binding sites, residues R7 and R9 of RgIA# are buried in the binding pockets forming salt-bridges with D201 and D121 of the (+) and () components, respectively ( Figure 3C,D) . Similarly, the conserved aspartate residues D201 and D121 were suggested to interact with RgIA residues R7 and R9, respectively, at the rα10(+)-α9() interface. 28 It was also proposed that R11 of RgIA interacts with E197 of the rα10 subunit. However, residue R11 of RgIA# is solvent exposed and flexible in our MD simulations, and only occasionally approaching E197 of the α10 and α9 (+) components forming unstable salt-bridges.
The DPR (Asp-Pro-Arg) motif is conserved in α-conotoxins ImI, RgIA# (or RgIA) and Vc1.1, and essential to their binding affinities. 26, [29] [30] [31] However, this sequence epitope is not present in PeIA despite its higher potency at inhibiting the hα9α10 nAChR than Vc1.1 and RgIA# (Figure 2, S1 ). In
PeIA, the side chain of H5 forms an internal hydrogen bond with C8 ( Figure S2 ), which might be essential to stabilize the secondary structure of the peptide. No remarkable differences were 
Energy calculations
Quantitative evaluation on the contribution of the principal site residues to Vc1.1, RgIA# and PeIA binding affinity was assessed using the MMGB/SA (molecular mechanics generalized Born/surface area) method ( Figure S3 ). Conserved residues on both α9 and α10 subunit (+) sites such as Y95, W151, T152, Y192, C194, C195, E197 and Y199 significantly contribute to the binding affinity of Figure S3B ) and PeIA ( Figure S3C ) showed minor contribution of α9 N154 and α10 G154 in the interactions with both α-conotoxins.
RgIA was suggested to have a high affinity binding site at the rat α10(+)-α9() interface based on the stoichiometry model of (α9) 2 (α10) 3 nAChR. 26 Our modeling studies showed comparable RgIA# binding energy at the principal subunits of α9(+) and α10(+) hence suggesting RgIA# has no binding preference for either α9(+)-α9() or α10(+)-α9() interfaces of the (α9) 
Electrophysiology
Injection of biased α9 to α10 subunit mRNA ratios resulted in putative (α9) 3 (α10) 2 and (α9) 2 (α10) 3 stoichiometries of the rα9α10 nAChRs heterologously expressed in X. laevis oocytes. 25 Consequently, a high-sensitivity Vc1.1 binding site was proposed at the α9(+)-α9() interface present only in the (α9) 3 (α10) 2 stoichiometry, and a low-sensitivity Vc1.1 binding site contributed by the α10(+)-α9() interface that exists in both stoichiometries. Most importantly, the stoichiometry of the rα9α10 nAChR expressed at 1:1 (or 10:1) and 1:3 ratios of α9:α10 mRNA was proposed to be (α9) 3 (α10) 2 /(α9) 4 (α10) 1 and (α9) 2 (α10) 3 nAChRs, respectively.
To validate our prediction that the hydrogen bond interaction between Vc1.1 D11-α9 and N154
is the determinant of Vc1.1 binding preference at the hα9(+)-α9() interface, residue N154 of the hα9 subunit was mutated to the corresponding hα10 subunit G154. We determined the biological activity of Vc1.1, RgIA#, PeIA and, analogues Vc1. charge interaction at both α9(+)α9(─) and α10(+)α9(─) interfaces as well as disruption to the hydrogen bond between N154 and D11 at the α9(+)α9(─) interface ( Figure 3A ,B). Using thermodynamic mutant cycles, 32 the coupling coefficient (Ω) gave a reciprocal of 28.57 suggesting a relatively strong coupling between Vc1.1 D11 and α9 N154 . Additionally, the coupling energy between Vc1.1 D11 and α9 N154 was calculated to be 1.95 kcal/mol, comparable to the hydrogen bond energy between N-H and O (~1.9 kcal/mol), 33 further demonstrating the key pairwise interaction between Vc1.1 D11 and α9 N154. 
Conclusion
Our computational modelling in combination with mutagenesis studies support that the stoichiometry of the hα9α10 nAChR expressed with α9:α10 mRNA injection ratios of 1:3 and 3:1 could correspond to (α9) 2 (α10) 3 and (α9) 3 (α10) 2 /(α9) 4 (α10) 1 nAChRs, respectively. The However, we cannot exclude the possibility of the α9(+)-α9(─) as an energetically favourable binding site of RgIA# at (α9) 3 (α10) 2 nAChR. Instead, our study suggests that the sensitivity of both α10(+)-α9(─) and α9(+)-α9(─) interfaces to RgIA# might be comparable. In a previous study, the contribution of α9 and α10 subunits to complementary components of the ligand-binding site was proposed to be non-equivalent, 34 whereas we found the contribution of α9 and α10 subunits to principal components of the ligand-binding site was non-equivalent for Vc1.1 binding but could be equivalent for the binding of RgIA# and PeIA.
In summary, elucidation of the determinants that confer the selectivity of the α-conotoxins to varied subunit arrangements of the hα9α10 nAChR is essential for rational design of novel stoichiometric-selective α-conotoxin analogues. Whether different stoichiometries of hα9α10 nAChR exist in vivo is yet to be determined. Regardless, stoichiometric-selective inhibitors of α9α10 nAChR would be useful neurochemical tools for further elucidating the functional differences between the stoichiometries in native cells. Conversely, α9α10 nAChR antagonists that do not discriminate between the stoichiometries, may be suitable candidates to use under conditions where different stoichiometries exist.
Methods
Homology modeling
Models of Vc1.1 bound h(α9) 2 (α10) 3 and h(α9) 2 (α10) 3 nAChRs were built using Modeller (version 9v14), as described previously. 24, 30 The extracellular domain sequence of the hα1, α3, α4, α6, α7, α9, and α10 nAChR subunits were retrieved from the Uniprot database. 35 
Molecular dynamic simulations
The protonation states of His, Asp and Glu residues at the conotoxin/nAChR complexes were predicted using the PropKa 3.1 method. 39 The models were minimized and refined using molecular dynamics (MD) simulations performed with the Amber 16 package and ff14SB force field. 40, 41 The receptor complexes were solvated in a truncated octahedral TIP3P water box containing ~10800 water molecules. Sodium ions were added to neutralize the systems. The systems were first minimized with 3,000 steps of steepest descent and then 3,000 steps of conjugate gradient with the solute restrained to their position by a harmonic force of 100 kcal/mol·Å 2 . A second minimization was then performed but with all position restraints withdrawn. The systems were then gradually heated up from 50 to 300 K in the NVT ensemble over 100 ps with the solute restrained to their position using a 5 kal/mol·Å 2 harmonic force potential. MD simulations were then carried out in the NPT ensemble, and the position restraints were gradually removed over 100 ps. The production runs were conducted over 50 ns simulation time with pressure coupling set at 1 atm and a constant temperature of 300 K. The MD simulations used a time step of 2 fs and, all bonds involving hydrogen atoms were maintained to their standard length using the SHAKE algorithm. 42 The particle-mesh Ewald (PME) method was used to model long-range electrostatic interactions. 43 MD trajectories were analyzed using VMD (http://www.ks.uiuc.edu/) and molecules were drawn using PyMol (Schrödinger, LLC).
For validation of the Vc1.1 analogue stability, 100 ns repeated MD simulations were performed on Vc1.1[N9D] and Vc1.1[PeIA] systems respectively, using the same method as described above.
Binding energy decomposition
To quantify the binding energy contribution of these key residues in the ligand binding site, binding energy decomposition was carried out using the MMPBSA.py script in AMBER16. 44 The binding free energy (ΔG binding ) values were calculated using the following equation:
where the binding free energy (ΔG binding ) was determined using MMGB/SA method. 45 This method was identified in our previous study as being slightly more efficient for ranking mutational energies based on homology models than the MMPB/SA method. Details of the MMGB/SA method on peptide binding energy calculation was described in our previous modelling studies. 30 
Thermodynamic mutant cycles
The coupling coefficient (Ω) and coupling energy (ΔG couple ) was determined using equations (2) and (3) where R = gas constant, T = temperature
Peptide synthesis
Procedures for solid peptide synthesis of Vc1.1 analogues were nearly the same as described previously. 24 Briefly, Vc1. H 2 O/0.045% TFA), and lyophilized. Crude peptides were purified by RP-HPLC on a Phenomenex C 18 column, and its molecular mass was confirmed using electrospray mass spectrometry before they were pooled and lyophilized for oxidation. The four cystines in the peptides were selectively oxidized in two steps. In the first step the non-protected cystines were oxidized in 0.1 M NH 4 HCO 3
(pH 8-8.5) at a concentration of 0.5 mg/ml, and stirred at room temperature overnight. In the second step, the Acm-protected cystines were oxidized by dissolving the peptides in iodine solution filled at concentration of 1 mg/ml, and stirred for 30 min. Ascorbic acid was then added to stop the oxidizing reaction and the solution was stirred again until no colour was visible. After two rounds of oxidation, peptides were purified by RP-HPLC and their mass ( Figure S7 ) and purity ( Figure S8) were validated using electrospray-mass spectrometry (MS) and analytical RP-HPLC, respectively.
Circular dichroism (CD) study
CD spectra were performed on Jasco J-810 spectropolarimeter over the wavelength range of 250-190 nm using a 1.0 mm path length cell, a bandwidth of 1.0 nm, a response time of 2 s, and averaging over three scans. Spectra were recorded at room temperature under nitrogen atmosphere. 
PCR site-directed mutagenesis
N154G mutation to the hα9 nAChR subunit in plasmid pT7TS was done using PrimeSTAR Max kit (Takara Bio, Kusatsu, Shiga, Japan). Mutation was confirmed by DNA sequencing (Australian Genome Research Facility, Melbourne, VIC, Australia).
In vitro cRNA synthesis
Plasmid pT7TS constructs of hα9 and hα10 nAChR subunits were linearized with XbaI restriction enzyme (NEB, Ipswich, MA) for in vitro cRNA transcription using T7 mMessage mMachine transcription kits (AMBION, Foster City, CA, USA).
Oocyte preparation and microinjection. 
Oocyte two-electrode voltage clamp recording and data analysis.
Electrophysiological recordings were carried out 2-5 days post cRNA microinjection.
Two-electrode voltage clamp recordings of X. laevis oocytes expressing human nAChRs were performed at room temperature (21−24 °C) using a GeneClamp 500B amplifier and pClamp9 software interface (Molecular Devices, Sunnyvale, CA, USA) at a holding potential ─80 mV.
Voltage-recording and current-injecting electrodes were pulled from GC150T-7.5 borosilicate glass 
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